Project Details
Description
The objective of this study is to evaluate the safety, tolerability and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with mRNA COVID-19 vaccine.
Layman's description
This is a Phase I/II/III, multicenter, randomized, double-blinded trial designed to evaluate the safety, tolerability and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with mRNA COVID-19 vaccine.
| Status | Finished |
|---|---|
| Effective start/end date | 22/12/21 → 1/01/23 |
Collaborative partners
- Sinocelltech Ltd. (lead)
Keywords
- COVID-19
- SARS-CoV-2
- Vaccine
- Pneumonia, Viral
- Pneumonia
- Respiratory Tract Infections
- Infections
- Virus Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Lung Diseases
- Respiratory Tract Diseases
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.